MCID: PRT018
MIFTS: 50

Portal Vein Thrombosis

Categories: Blood diseases, Cardiovascular diseases, Gastrointestinal diseases

Aliases & Classifications for Portal Vein Thrombosis

MalaCards integrated aliases for Portal Vein Thrombosis:

Name: Portal Vein Thrombosis 12 73 29 54 15 70 32

Classifications:



External Ids:

Disease Ontology 12 DOID:11695
ICD9CM 34 452
NCIt 50 C78565
SNOMED-CT 67 155455003
ICD10 32 I81
UMLS 70 C0155773

Summaries for Portal Vein Thrombosis

Disease Ontology : 12 A hepatic vascular disease that is characterized by a blood clot that forms within the hepatic portal vein.

MalaCards based summary : Portal Vein Thrombosis is related to varicose veins and esophageal varix. An important gene associated with Portal Vein Thrombosis is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Collagen chain trimerization. The drugs Warfarin and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and endothelial, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 73 Portal vein thrombosis (PVT) is a vascular disease of the liver that occurs when a blood clot occurs in... more...

Related Diseases for Portal Vein Thrombosis

Diseases related to Portal Vein Thrombosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 535)
# Related Disease Score Top Affiliating Genes
1 varicose veins 31.5 SERPINC1 PLAT MTHFR F5 F2
2 esophageal varix 31.5 SERPINC1 F2 AFP
3 hepatic coma 31.3 SERPINC1 F2 AFP
4 splenomegaly 31.1 MPL JAK2 IFNA1
5 liver cirrhosis 31.0 SERPINC1 IFNA1 F2 CRP AFP
6 peritonitis 31.0 SELP F2 CRP
7 beta-thalassemia major 30.8 MTHFR F5 F2
8 cryptogenic cirrhosis 30.8 SERPINE1 MTHFR F5 F2
9 paroxysmal nocturnal hemoglobinuria 30.7 SERPINC1 SELP MPL F2
10 acute cholangitis 30.7 F2 CRP
11 eclampsia 30.6 SERPINC1 MTHFR F2
12 homocystinuria 30.6 SERPINC1 MTHFR F5
13 antithrombin iii deficiency 30.6 SERPINC1 MTHFR JAK2 F5 F2 APOH
14 prothrombin thrombophilia 30.5 MTHFR F2
15 abdominal tuberculosis 30.5 F2 CRP AFP
16 hepatic veno-occlusive disease 30.5 SERPINE1 SERPINC1 PLAT
17 hepatic infarction 30.5 SERPINC1 F2 APOH AFP
18 protein s deficiency 30.4 SERPINC1 PROC MTHFR F5 F2 APOH
19 homocysteinemia 30.4 SERPINE1 SERPINC1 MTHFR F5 F2 CRP
20 pregnancy loss, recurrent 1 30.4 F5 APOH
21 splenic abscess 30.4 F2 CRP
22 ascending cholangitis 30.4 F2 CRP
23 cauda equina syndrome 30.4 F2 CRP
24 active peptic ulcer disease 30.4 F7 F2 CRP
25 thrombosis 30.3 SERPINE1 SERPINC1 SELP PROC PLAT PIGM
26 thrombophilia due to activated protein c resistance 30.3 SERPINE1 SERPINC1 MTHFR F5 F2 APOH
27 factor viii deficiency 30.3 SERPINC1 F7 F5 F2
28 myeloproliferative neoplasm 30.3 MPL JAK2 IFNA1 CALR
29 lemierre's syndrome 30.3 MTHFR F2 CRP
30 severe pre-eclampsia 30.3 SERPINC1 F5 APOH
31 polycythemia 30.3 SERPINC1 MPL JAK2 F5 F2 CALR
32 protein c deficiency 30.2 SERPINE1 SERPINC1 PROC MTHFR F5 F2
33 beta-thalassemia 30.2 SERPINC1 MTHFR JAK2 F5 F2 CRP
34 compartment syndrome 30.2 SERPINC1 F7 F2 CRP
35 thrombocytosis 30.2 SERPINC1 SELP MPL JAK2 F2 CRP
36 bilirubin metabolic disorder 30.2 SERPINC1 F2 CYP2C9 CRP AFP
37 cholangitis, primary sclerosing 30.2 F2 CRP AFP
38 splenic infarction 30.1 SERPINC1 JAK2 F2 CRP APOH
39 hepatic tuberculosis 30.0 F2 CRP AFP
40 purpura 30.0 SERPINC1 PROC MPL F2 CRP APOH
41 thrombophilia due to thrombin defect 30.0 SERPINE1 SERPINC1 PROC PLAT MTHFR F5
42 exanthem 30.0 IFNA1 F2 CRP
43 inflammatory bowel disease 29.9 SERPINC1 SELP MTHFR JAK2 F5 F2
44 afibrinogenemia, congenital 29.9 SERPINE1 SERPINC1 PLAT F7 F2
45 antiphospholipid syndrome 29.9 SERPINE1 SERPINC1 SELP PLAT MTHFR F5
46 hepatitis d 29.8 IFNA1 F2 CYP2C9
47 disseminated intravascular coagulation 29.8 SERPINE1 SERPINC1 PLAT F7 F5 F2
48 viral hepatitis 29.7 IFNA1 F2 CRP AFP
49 intracranial embolism 29.7 SERPINC1 SELP PLAT F2 CRP
50 hepatitis a 29.6 IFNA1 F2 AFP

Comorbidity relations with Portal Vein Thrombosis via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Vascular Insufficiency of Intestine
Hepatic Encephalopathy Portal Hypertension

Graphical network of the top 20 diseases related to Portal Vein Thrombosis:



Diseases related to Portal Vein Thrombosis

Symptoms & Phenotypes for Portal Vein Thrombosis

GenomeRNAi Phenotypes related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

26 (show all 26)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.74 IFNA1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-117 9.74 AFP
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.74 CRP
4 Increased shRNA abundance (Z-score > 2) GR00366-A-14 9.74 IFNA1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-141 9.74 APOH
6 Increased shRNA abundance (Z-score > 2) GR00366-A-145 9.74 IFNA1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.74 CRP
8 Increased shRNA abundance (Z-score > 2) GR00366-A-148 9.74 CRP
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.74 CRP
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.74 IFNA1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-173 9.74 MTHFR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-175 9.74 IFNA1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.74 MTHFR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.74 AFP
15 Increased shRNA abundance (Z-score > 2) GR00366-A-209 9.74 IFNA1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.74 MTHFR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.74 MTHFR
18 Increased shRNA abundance (Z-score > 2) GR00366-A-48 9.74 AFP
19 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.74 MTHFR
20 Increased shRNA abundance (Z-score > 2) GR00366-A-61 9.74 IFNA1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.74 CRP
22 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.74 MTHFR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.74 IFNA1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.74 IFNA1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.74 IFNA1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-89 9.74 AFP

MGI Mouse Phenotypes related to Portal Vein Thrombosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.07 CALR F2 F5 F7 JAK2 MPL
2 cardiovascular system MP:0005385 10.06 CALR CRP F2 F5 F7 JAK2
3 homeostasis/metabolism MP:0005376 10.03 AFP APOH CALR CRP F2 F5
4 liver/biliary system MP:0005370 9.61 AFP F5 JAK2 MTHFR PIGM PROC
5 mortality/aging MP:0010768 9.5 AFP APOH CALR F2 F5 F7

Drugs & Therapeutics for Portal Vein Thrombosis

Drugs for Portal Vein Thrombosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Warfarin Approved Phase 4 81-81-2 54678486 6691
2
tannic acid Approved Phase 4 1401-55-4
3
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
4
Nadroparin Approved, Investigational Phase 4
5
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
6
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
7
Dalteparin Approved Phase 4 9005-49-6
8
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
9
Dipyridamole Approved Phase 4 58-32-2 3108
10
Apixaban Approved Phase 4 503612-47-3 10182969
11
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
12
Chlorotrianisene Investigational, Withdrawn Phase 4 569-57-3 11289
13 Anticoagulants Phase 4
14 Fibrinolytic Agents Phase 4
15 Hormones Phase 4
16 Calcium, Dietary Phase 4
17 Pharmaceutical Solutions Phase 4
18 Gelatin Sponge, Absorbable Phase 4
19 Heparin, Low-Molecular-Weight Phase 4
20 Vasodilator Agents Phase 4
21 Serine Proteinase Inhibitors Phase 4
22 Factor Xa Inhibitors Phase 4
23 Antithrombin III Phase 4
24
protease inhibitors Phase 4
25 Antithrombins Phase 4
26 HIV Protease Inhibitors Phase 4
27 Analgesics, Non-Narcotic Phase 4
28 Analgesics Phase 4
29 Cyclooxygenase Inhibitors Phase 4
30 Antirheumatic Agents Phase 4
31 Antipyretics Phase 4
32 Phosphodiesterase Inhibitors Phase 4
33 Anti-Inflammatory Agents Phase 4
34 Anti-Inflammatory Agents, Non-Steroidal Phase 4
35 Platelet Aggregation Inhibitors Phase 4
36
Calcium Nutraceutical Phase 4 7440-70-2 271
37
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
38
Rivaroxaban Approved Phase 3 366789-02-8
39
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
40 Anti-Arrhythmia Agents Phase 3
41 Adrenergic Antagonists Phase 3
42 Adrenergic Agents Phase 3
43 Antihypertensive Agents Phase 3
44 Neurotransmitter Agents Phase 3
45 Protein Kinase Inhibitors Phase 3
46
Lenvatinib Approved, Investigational Phase 2 417716-92-8
47 Liver Extracts Phase 1, Phase 2
48
Entecavir Approved, Investigational Phase 1 142217-69-4 153941
49
Telbivudine Approved, Investigational Phase 1 3424-98-4 159269
50
Axitinib Approved, Investigational Phase 1 319460-85-0 6450551

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis:A Zelen-design Multicenter Randomized Controlled Trial Unknown status NCT02630095 Phase 4 Nadroparin Calcium and Warfarin
2 A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
3 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Unknown status NCT02238444 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
4 Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis Completed NCT03007212 Phase 4
5 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy and Azygoportal Disconnection for Portal Hypertension Completed NCT02247414 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
6 Efficacy and Safety of Nadroparin Calcium-Warfarin Sequential Anticoagulation in Portal Vein Thrombosis in Cirrhotic Patients:A Randomized Controlled Trial Completed NCT04173429 Phase 4 Nadroparin calcium, warfarin
7 Efficacy and Safety of Apixaban, Warfarin and Aspirin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy Recruiting NCT04645550 Phase 4 Apixaban;Warfarin;Aspirin;Dipyridamole;Low molecular weight heparin
8 Minimal Hepatic Encephalopathy in Pre-hepatic Portal Hypertension Due to Portal Vein Thrombosis in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study. Unknown status NCT01798329 Phase 3
9 Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study Unknown status NCT02627053 Phase 3 rivaroxaban
10 Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis Unknown status NCT03193502 Phase 3 rivaroxaban
11 Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis (PVT) and Cavernous Transformation of the Portal Vein (CTPV) Unknown status NCT02853526 Phase 3 Propranolol;Warfarin
12 Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis Completed NCT02250391 Phase 3 NPB-06;Placebo
13 Multicentric Randomized Study of Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. Completed NCT02555111 Phase 3 Xarelto
14 A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT) Terminated NCT01887717 Phase 3 Sorafenib
15 An Investigator-initiated, Multicentre, Randomized, Trial Comparing Anticoagulation Alone Versus Transjugular Intrahepatic Portosystemic Shunt (TIPS) and Anticoagulation in Patients With Recent Obstructive Portal Vein Thrombosis Withdrawn NCT03422419 Phase 3 Heparin
16 Pneumatic Reversible Portal Vein Diameter Modulation After Major Hepatectomy in Non Cirrhotic Patient Unknown status NCT02390713 Phase 1, Phase 2
17 Phase II Study of Concurrent Lenvatinib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma Recruiting NCT04791176 Phase 2
18 Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma Active, not recruiting NCT03535259 Phase 2
19 Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698 Terminated NCT00769873 Phase 2 Enoxaparin
20 A Phase I Clinical Trial Evaluating the Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for Advanced Hepatocellular Carcinoma (HCC) Completed NCT02814461 Phase 1 Axitinib
21 Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis: A Randomized, Double-blinded, Placebo - Controlled Trial (PiVoT-AC Trial) Active, not recruiting NCT04055389 Phase 1 Antithrombin III
22 Role of Endoscopic Ultrasound Guided Fine Needle Aspiration of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular Carcinoma Unknown status NCT03902678
23 The Effect of Rifaximin on Portal Vein Thrombosis in Cirrhotic Patients Unknown status NCT03631147 Rifaximin
24 Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) or Portal Vein Thrombosis Unknown status NCT02309788
25 Trans-arterial Radioembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis Completed NCT04771988
26 A Humanitarian Device Exemption Treatment Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma in Patients With Portal Vein Thrombosis Completed NCT01556282
27 Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis Completed NCT03201367 Rivaroxaban
28 Proteomic Analysis of Human Hepatocellular Carcinoma Associated With Portal Vein Thrombosis Completed NCT01177631
29 Portal Vein Thrombosis Relevance On Liver Cirrhosis: Italian Venous Thrombotic Events Registry Completed NCT01470547
30 Pair Production PET Imaging to Detect Particle Distribution in Patients Undergoing Yttrium-90 Radioembolization With Large Hepatocellular Carcinomas or Associated Portal Vein Thrombosis Completed NCT02848638
31 Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms Completed NCT01816256
32 Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Treatment Combined With Propranolol for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis: A Randomized Controlled Trial Completed NCT01326949
33 Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis Completed NCT02069457
34 Ultrasound Elastography Assessment of Spleen and Liver Stiffness Before and After Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure Recruiting NCT03427164
35 Follow-up and Survival of Cirrhotic and Non Cirrhotic Patients With Portal Vein Thrombosis Treated With Transjugular Intrahepatic Portosystemic Shunt Recruiting NCT03031717
36 Comparison in Portal Flow After Sleeve Gastrectomy and Mini Gastric Bypass Recruiting NCT02733770
37 TIPS Versus Endoscopic Therapy for the Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis: A Randomized Controlled Trial Recruiting NCT02485184 Non-selective beta blockers;Anticoagulation
38 Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis: A Single-center, Prospective, Cohort Study Recruiting NCT02335580 Somatostatin and its analogs
39 Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis-A Randomized Placebo Controlled Trial Recruiting NCT04433481 Dabigatran
40 Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy in a High-volume Center. A Cohort Study. Recruiting NCT02597218
41 STUDY OF THE ADAMTS-13 LEVEL AS PREDICTIVE BIOMARKER FOR DEVELOPMENT OF PORTAL VEIN THROMBOSIS IN LIVER CIRRHOSIS Active, not recruiting NCT03322696
42 A Prospective and Multicentric Cohort Study Evaluating the Complications of Portal Vein Thrombosis in Patients With Locally Advanced Pancreatic Cancer : THROMPAN Not yet recruiting NCT04814251
43 A Prospective Randomized Controlled Trial Comparing Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis Withdrawn NCT01659346 Carvedilol
44 Efficacy and Safety of Acenocoumarol for Treatment of Nontumor Portal Vein Thrombosis in Cirrhosis of Liver Withdrawn NCT01631877 Enoxaparin with acenocoumarol
45 Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis: a Single Center Prospective Randomized Controlled Trial Withdrawn NCT02526303 Nadroparin Calcium and Warfarin
46 Portal Vein Thrombosis in Cirrhosis: A Cohort Sudy Withdrawn NCT02275585

Search NIH Clinical Center for Portal Vein Thrombosis

Genetic Tests for Portal Vein Thrombosis

Genetic tests related to Portal Vein Thrombosis:

# Genetic test Affiliating Genes
1 Portal Vein Thrombosis 29

Anatomical Context for Portal Vein Thrombosis

MalaCards organs/tissues related to Portal Vein Thrombosis:

40
Liver, Spleen, Endothelial, Colon, Pancreas, Myeloid, Neutrophil

Publications for Portal Vein Thrombosis

Articles related to Portal Vein Thrombosis:

(show top 50) (show all 3888)
# Title Authors PMID Year
1
Portal vein thrombosis treated using danaparoid sodium and antithrombin III. 61 54
20422871 2010
2
Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism. 61 54
19864937 2010
3
Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. 61 54
20305756 2009
4
Resolution of preoperative portal vein thrombosis after administration of antithrombin III in living donor liver transplantation: case report. 54 61
19917415 2009
5
Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. 61 54
18331238 2009
6
Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. 54 61
19067476 2009
7
Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology. 61 54
19024130 2008
8
Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study. 61 54
18699979 2008
9
Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. 54 61
18023093 2007
10
High FVIII level is associated with idiopathic portal vein thrombosis in South India. 61 54
17524760 2007
11
Idiopathic portal vein thrombosis and FVIII levels. 54 61
17011614 2007
12
A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization. 61 54
17416468 2007
13
Factor V Leiden and prothrombin gene G20210A mutations are uncommon in portal vein thrombosis in India. 54 61
17090840 2006
14
[Modified CLIP score as a new prognostic index for patients with hepatocellular carcinoma]. 61 54
16804346 2006
15
Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. 61 54
16773687 2006
16
Factor V Leiden is not commonly associated with idiopathic portal vein thrombosis in southern India. 54 61
16877827 2006
17
[Survival analysis for patients with hepatocellular carcinoma according to stage, liver function and treatment modalities]. 61 54
16565605 2006
18
Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation. 54 61
16493481 2006
19
Mesenteric and portal vein thrombosis associated with hyperhomocysteinemia and heterozygosity for factor V Leiden mutation. 54 61
16437705 2005
20
Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. 61 54
15947552 2005
21
Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. 61 54
15710992 2005
22
Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study. 54 61
15309526 2004
23
Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. 61 54
15466827 2004
24
Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. 61 54
15209629 2004
25
Portal vein thrombosis complicating islet transplantation in a recipient with the Factor V Leiden mutation. 54 61
15257060 2004
26
Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: a study from North India. 61 54
15198356 2004
27
Pathologic analysis of right-lobe graft failure in adult-to-adult live donor liver transplantation. 54 61
14615823 2003
28
[Portal vein thrombosis associated with factor V Leiden mutation in a woman who underwent exchange transfusion at birth]. 54 61
12910230 2003
29
[Thrombophilic disorders in children and adolescents with portal vein thrombosis]. 61 54
14502338 2003
30
Detection of circulating hepatocellular carcinoma cells in peripheral venous blood by reverse transcription-polymerase chain reaction. 61 54
14607627 2002
31
Plasma thrombopoietin in patients with cavernous transformation of the portal vein. 61 54
11843299 2002
32
[Relation between transcatheter arterial chemoembolization and time of death in patients with hepatic carcinoma]. 54 61
11859720 2001
33
Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. 54 61
11584361 2001
34
Hepatocellular carcinoma in Central Europe: prognostic features and survival. 54 61
11115830 2001
35
Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. 54 61
11129271 2000
36
Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors - a multicentre case-control study. For the Childhood Thrombophilia Study Group. 61 54
11122096 2000
37
Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. 61 54
11001884 2000
38
Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. 54 61
10733537 2000
39
Deficiency of natural anticoagulant proteins C, S, and antithrombin in portal vein thrombosis: a secondary phenomenon? 54 61
10716684 2000
40
The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis. 54 61
10636214 2000
41
Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan. 61 54
10463978 1999
42
[Resistance to activated protein C and portal vein thrombosis: two new cases and review of the literature]. 61 54
10434351 1999
43
Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. 54 61
9869612 1999
44
Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection--a single-center analysis including 132 patients. 61 54
9842968 1998
45
[The detection of circulating hepatocellular carcinoma cells in peripheral venous blood by reverse transcription-polymerase chain reaction and its clinical significance]. 61 54
11825477 1998
46
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. 54 61
9731568 1998
47
[Successful treatment of hepatocellular carcinoma with All-trans-retinoic acid]. 61 54
9569727 1998
48
Portal vein thrombosis in association with factor V Leiden mutation in a patient with hepatocellular carcinoma. 61 54
9212850 1997
49
Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. 61 54
9245936 1997
50
Factor V Leiden is not common in children with portal vein thrombosis. 61 54
9157577 1997

Variations for Portal Vein Thrombosis

Expression for Portal Vein Thrombosis

Search GEO for disease gene expression data for Portal Vein Thrombosis.

Pathways for Portal Vein Thrombosis

Pathways related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.88 SERPINE1 SELP JAK2 IFNA1 CYP2C9 CALR
2
Show member pathways
12.5 SERPINC1 PROC F7 F5 F2
3
Show member pathways
12.48 SERPINE1 SERPINC1 SELP PROC PLAT MPL
4
Show member pathways
12.07 SERPINE1 PLAT MTHFR F7 F2 CRP
5
Show member pathways
11.9 SERPINE1 SERPINC1 PROC PLAT F7 F5
6
Show member pathways
11.67 PROC F7 F2
7 11.66 SERPINE1 SERPINC1 PROC PLAT F7 F5
8 11.63 MPL JAK2 CRP
9 10.67 PROC F7 F2
10 10.55 SERPINE1 PLAT

GO Terms for Portal Vein Thrombosis

Cellular components related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.03 SERPINE1 SERPINC1 PROC PLAT IFNA1 F7
2 collagen-containing extracellular matrix GO:0062023 9.7 SERPINE1 SERPINC1 PLAT F7 F2 CALR
3 Golgi lumen GO:0005796 9.5 PROC F7 F2
4 endoplasmic reticulum lumen GO:0005788 9.5 SERPINC1 PROC F7 F5 F2 CALR
5 extracellular space GO:0005615 9.44 SERPINE1 SERPINC1 SELP PROC PLAT IFNA1

Biological processes related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.83 SERPINC1 PROC F5 F2 AFP
2 ER to Golgi vesicle-mediated transport GO:0006888 9.78 PROC F7 F5 F2
3 platelet degranulation GO:0002576 9.76 SERPINE1 SELP F5 APOH
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.69 SELP JAK2 F2
5 fibrinolysis GO:0042730 9.58 SERPINE1 PLAT F2
6 negative regulation of blood coagulation GO:0030195 9.54 SERPINE1 PROC APOH
7 blood coagulation, intrinsic pathway GO:0007597 9.52 F2 APOH
8 regulation of blood coagulation GO:0030193 9.5 SERPINC1 F2 APOH
9 plasminogen activation GO:0031639 9.49 PLAT APOH
10 positive regulation of blood coagulation GO:0030194 9.46 SERPINE1 F7 F2 APOH
11 negative regulation of fibrinolysis GO:0051918 9.43 SERPINE1 F2 APOH
12 hemostasis GO:0007599 9.35 SERPINC1 PROC F7 F5 F2
13 blood coagulation GO:0007596 9.23 SERPINC1 PROC PLAT JAK2 IFNA1 F7

Molecular functions related to Portal Vein Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.8 SELP PROC F7 F2 CRP CALR
2 signaling receptor binding GO:0005102 9.65 SERPINE1 PLAT JAK2 F7 F2
3 serine-type endopeptidase activity GO:0004252 9.46 PROC PLAT F7 F2
4 complement component C1q binding GO:0001849 9.37 CRP CALR
5 heparin binding GO:0008201 9.26 SERPINC1 SELP F2 APOH
6 serine-type peptidase activity GO:0008236 8.92 PROC PLAT F7 F2

Sources for Portal Vein Thrombosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....